The data were presented at the European Respiratory Society (ERS) International Congress 2018 in Paris, France, and published in The Lancet Respiratory Medicine.ĭr Colin Reisner, Head of Respiratory, Global Medicines, said: “We are encouraged by the results of the KRONOS trial which demonstrate PT010’s efficacy in improving lung function and its potential value as a triple combination therapy for patients with COPD. Further details on the primary endpoints are outlined below. The incidence of adjudicated pneumonia was low and comparable in all treatment arms. PT010 also demonstrated reductions in the rate of moderate or severe COPD exacerbations versus PT009 and Symbicort (18% and 17% respectively), which were numerically but not statistically significant improvements. The KRONOS trial met eight of the nine primary lung function endpoints and, in a key secondary endpoint, PT010 showed a statistically significant 52% reduction in the rate of moderate or severe COPD exacerbations compared with Bevespi Aerosphere in a patient population that was not required to have had an exacerbation in the previous 12 months. United Kingdom, Monday, September 17, 2018, 18:00 Hrs ĪstraZeneca announced publication of results from the KRONOS phase III trial which evaluated the efficacy and safety of triple combination therapy PT010 (budesonide/ glycopyrronium /formoterol fumarate) versus dual combination therapies Bevespi Aerosphere (glycopyrronium/ formoterol fumarate), Symbicort Turbuhaler (budesonide/ formoterol fumarate) and PT009 (budesonide/ formoterol fumarate) in patients with moderate to very severe chronic obstructive pulmonary disease (COPD) regardless of whether or not they had an exacerbation in the prior year. AstraZeneca announces positive results from KRONOS phase III trial for PT010 triple combo therapy in moderate to very severe COOD
0 Comments
Leave a Reply. |
AuthorWrite something about yourself. No need to be fancy, just an overview. ArchivesCategories |